Amazon Biotech, Inc. Announces Issuance of Patent for a Unique Formulation and Method of Treating HIV Infection
Friday , February 16, 2007 16:15ET
NEW YORK, NY -- (MARKET WIRE) -- 02/16/07 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) announced that it has been issued a patent from the United States Patent and Trademark Office, patent # 7,160,561 for "a herbal composition and method of treating HIV infection."
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
-------------------------------------------------------------------------------- Contact: LC Group Rick Lutz (404) 261-1196
Source: Amazon Biotech, Inc
-------------------- " Cash is King " Posts: 1102 | From: NJ | Registered: Mar 2006
| IP: Logged |
Harbinger Research Issues Research Brief for Amazon Biotech Inc. With a Speculative Buy Rating and Price Target of $0.25
NEW YORK, NY--(MARKET WIRE)--Feb 16, 2007 -- Harbinger Research LLC, www.harbingerresearch.com , an independent research firm, issued a Research Brief today for Amazon Biotech, Inc. (OTC BB:AMZB.OB - News ), a development stage pharmaceutical/biotech company that is developing an all natural drug (AMZ 0026) for the treatment of HIV/AIDS.
The report provides a description of Amazon Biotech's business, industry, product, strategy, management team, and investment opportunities and risks. The report also includes a rating and price target.
Harbinger Research is a quality-leading New York based independent equity research company that provides insightful, in-depth equity research coverage and informational reports to smaller U.S. traded companies and the individuals and institutions that invest in them.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Harbinger Research Contact: Brian R. Connell, CFA Chief Executive Officer
bconnell*harbingerresearch.com
Statement under the Private Securities Litigation Reform Act: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements. Harbinger Research, LLC received US$5,000 from a third party in return for report authoring and distribution services.
Contact: Contact: LC Group Rick Lutz (404) 261-1196
-------------------------------------------------------------------------------- Source: Amazon Biotech, Inc.
-------------------- " Cash is King " Posts: 1102 | From: NJ | Registered: Mar 2006
| IP: Logged |
posted
Start about 30 threads, maybe that will pump it ?
-------------------- A million seconds is 13 days. A billion seconds is 31 years. Posts: 4893 | From: Burbank IL USA | Registered: Feb 2004
| IP: Logged |
Short Term Indicators 7 Day Average Directional Indicator Sell 10 - 8 Day Moving Average Hilo Channel Hold 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Sell 20 Day Bollinger Bands Hold
Short Term Indicators Average: 20% - Sell 20-Day Average Volume - 230230
Medium Term Indicators 40 Day Commodity Channel Index Hold 50 Day Moving Average vs Price Sell 20 - 100 Day MACD Oscillator Sell 50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 25% - Sell 50-Day Average Volume - 266572
Long Term Indicators 60 Day Commodity Channel Index Hold 100 Day Moving Average vs Price Sell 50 - 100 Day MACD Oscillator Sell
Long Term Indicators Average: 67% - Sell 100-Day Average Volume - 202093
Overall Average: 40% - Sell
Price Support Pivot Point Resistance
0.0750 0.0563 0.0703 0.0843
AMZB:US Amazon Biotech Inc
Industry: Medical-Biomedical/Gene Add Security to your Watch List
02/16 OTC BB Currency: USD
Price 0.075 Change N.A. % Change N.A. Bid 0.075 Ask 0.080 Open 0.075 Volume 33,500 High 0.075 Low 0.061 52-Week High 0.36 (04/04/06) 52-Week Low 0.06 (01/30/07) 1-Yr Return -53.125%
EARNINGS
Earnings Past 12 Months N.A. Quarter Est. EPS() N.A. Quarter Est. EPS() N.A. Year Est. EPS() N.A. Price/Earnings (Trailing) N.A. Relative P/E N.A. Earnings Growth Rate N.A. Estimated P/E N.A.
FUNDAMENTALS
Shares (Millions) 41.688 Market Cap (Millions) 3.127 Float (Millions) 37.786 Return on Equity N.A. Short Interest N.A. Last Dividend Reported N.A. Dividend Yield (Trailing 12mo.) N.A. Relative Dividend Yield N.A.
Price for AMZB:USSECTOR COMPARATIVE RETURNS
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Anyone know the recent O/S? They have issued close to double the 24 million since that time in Oct 2004, just a quick eyeball figure. So it is around 50 million, which is still low. TIA
Posts: 316 | Registered: Oct 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
